)
Business philosophy12 Aug 2025
Maziar Mike Doustdar: Novo Nordisk's New CEO
A portrait of the pharmaceutical giant's new CEO, who assumes the position at a critical time for the company in its competition with Eli Lilly.
Eli Lilly and Company
Eli Lilly and Company (LLY) investor relations material
Eli Lilly and Company Investor presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Investor presentation summary30 Sep, 2026
Portfolio highlights
Zepbound is the leading prescribed medicine for obesity, while Mounjaro is the top incretin for type 2 diabetes.
Foundayo's U.S. obesity launch is ongoing, with global rollout and type 2 diabetes approval expected in 2026/2027.
Foundayo, Retatrutide, and EloraTZP are positioned to raise the standard of care in cardiometabolic health.
Clinical trial results
Foundayo demonstrated cardiovascular safety, sustained glycemic control, and weight loss in the ACHIEVE-4 trial, with a 16% lower risk of MACE-4 and 23% lower risk of MACE-3 events compared to insulin glargine.
Retatrutide achieved up to 20.8% weight loss at 80 weeks in patients with obesity and type 2 diabetes in the TRIUMPH-2 study.
EloraTZP delivered up to 23% weight loss at 48 weeks in a Phase 2 study, with the high-dose combination outperforming monotherapies.
Safety and tolerability
Retatrutide's most common adverse events were gastrointestinal, with most being mild to moderate and resolving during treatment.
Eloralintide showed favorable GI tolerability, and EloraTZP's adverse event profile was consistent with other incretin therapies.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Eli Lilly and Company
- Obesity treatment portfolio expands with new therapies, digital access, and strong cost-effectiveness data.LLY
Morgan Stanley 24th Annual Global Healthcare Conference - Q2 2026 revenue surged 48% to $23B, driving raised guidance and strong product momentum.LLYQ2 2026
- Expanding supply and access for obesity and diabetes drugs, with a strong late-stage pipeline.LLYGoldman Sachs 45th Annual Global Healthcare Conference
- Q3 2025 revenue jumped 54% to $17.6B, with EPS and guidance raised on strong product demand.LLYQ3 2025
- Orforglipron and retatrutide lead a robust pipeline targeting obesity and diabetes, with global launches by 2027.LLYInvestor Update
- Q3 revenue up 20% to $11.44B (42% ex-olanzapine), led by Mounjaro and Zepbound growth.LLYQ3 2024
- Q2 revenue up 36% with $3B guidance raise, strong EPS growth, and major pipeline progress.LLYQ2 2024
- Q1 2025 revenue up 45% to $12.73B, driven by Mounjaro and Zepbound growth.LLYQ1 2025
- Q4 revenue up 45% and EPS more than doubled; 2025 guidance signals strong growth.LLYQ4 2024
Next Eli Lilly and Company earnings date
Q3 202629 Oct, 2026
Eli Lilly and Company
Next Eli Lilly and Company earnings date
Q3 202629 Oct, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge8 Aug 2025
Novo Nordisk: Tipping the Scale of Innovation
Taking a look at the company behind Ozempic and Wegovy and diving into their history, business, and the challenges it now faces.
)
Business philosophy3 Jul 2025
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
Frequently asked questions
Explore our global coverage